학술논문
Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions — VISION Network, September 2023–February 2024
Document Type
Article
Author
Link-Gelles, R.; Fleming-Dutra, K.E.; Okwuazi, E.; Shah, A.B.; Wiegand, R.; Payne, A.B.; Rowley, E.A.K.; Weber, Z.A.; Reese, S.E.; Ball, S.W.; Dunne, M.M.; DeSilva, M.B.; McEvoy, C.E.; Akinsete, O.; Dascomb, K.; Irving, S.A.; Naleway, A.L.; Klein, N.P.; Zerbo, O.; Fireman, B.; Hansen, J.; Goddard, K.; Grannis, S.J.; Dixon, B.E.; Rogerson, C.; Fadel, W.F.; Duszynski, T.; Ong, T.C.; Rao, S.; Barron, M.A.; Bride, D.; Sheffield, T.; Natarajan, K.; Tenforde, M.W.
Source
In: Morbidity and Mortality Weekly Report . (Morbidity and Mortality Weekly Report, 28 March 2024, 73(12):271-276)
Subject
Language
English
ISSN
1545861X
01492195
01492195